Search for Clinical Trial Results

Sponsored By

Neurofibromatosis 2 - 25 Studies Found

Status Study
Completed Study Name: An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
Condition: Neurofibromatosis 2
Date: 2002-01-30
Interventions: Device: Penetrating auditory brainstem implant
Completed Study Name: Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
Condition: Neurofibromatosis 2
Date: 2011-11-30
Interventions: Drug: RAD001 10 mg per os / day or 05mg per os / day with 12 month
Suspended Study Name: PTC299 for Treatment of Neurofibromatosis Type 2
Condition: Neurofibromatosis 2
Date: 2009-05-28
Interventions: Drug: PTC299 PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until t
Recruiting Study Name: AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Condition:
  • Neurofibromatosis 2
  • Meningioma

Date: 2016-07-07
Interventions: Drug: AZD2014
Completed Study Name: Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
Condition: Neurofibromatosis 2
Date: 1999-10-18
Interventions: Device: Multichannel Auditory Brain Stem Implant
Recruiting Study Name: Resiliency Training for Patients With NF2 Via Videoconferencing With Skype
Condition: Neurofibromatosis 2
Date: 2016-06-21
Interventions:
  • Behavioral: Stress Management Group 1

Completed Study Name: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Condition: Neurofibromatosis Type II
Date: 2011-08-17
Interventions: Drug: Everolimus (RAD001) , Afinitor® Everolimus will be provided by Novartis. Everolimus is formul
Completed Study Name: Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Condition:
  • Neurofibromatosis 2
  • Vestibular Schwannoma

Date: 2009-09-03
Interventions: Drug: Lapatinib Lapatinib is dosed according to age. Lapat
Active, not recruiting Study Name: Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Condition:
  • Neurofibromatosis Type 2
  • Progressive Vestibular Schwannomas Date: 2013-01-07
    Interventions: Drug: Bevacizumab Treatment will be administered on an out
Recruiting Study Name: Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Condition:
  • Vestibular Schwannoma
  • Neurofibromatosis Type 2

Date: 2016-10-13
Interventions: Drug: Icotinib Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Tot
Next >>>